Merck just dashed the last remaining hopes for its industry-leading BACE drug for Alzheimer's
The Alzheimer’s field is keeping its perfect record for failure in pivotal Phase III studies.
Merck today scrapped the last remaining Phase III study of its leading BACE therapy verubecestat, the second of two collapsed studies, after independent monitors concluded that the drug wasn’t working for early-stage, prodromal patients.
Back in February Merck signaled its lack of success with the drug, which moves upstream to reduce the production of amyloid beta, when it punted its Phase III trial in mild-to-moderate patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.